3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 3
3
Phase 4
1
Phase 1
1
Status
Terminated
2
Unknown
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
3
Lymphoid
3
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
7
Neoplasms
4
Leukemia, B-Cell
3
Recurrence
2
Leukemia
2
Bronchiolitis Obliterans Syndrome
2
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Autoimmune Diseases of the Nervous System
1
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
1
Interventions
ofatumumab
3
venetoclax
2
pirtobrutinib
2
obinutuzumab
2
ibrutinib
2
Chlorambucil
2
acalabrutinib
1
Tablets
1
Observation
1
Cholecalciferol
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, B-Cell
×
ofatumumab
×
Clear all
NCT01039376
2019-07-30
PROLONG
Novartis
Phase 3
Terminated
480 enrolled
30 charts
NCT00748189
2019-06-25
COMPLEMENT 1
Novartis
Phase 3
Terminated
447 enrolled
32 charts
NCT01678430
2012-10-15
RIAltO
University of Liverpool
Phase 3
Unknown
670 enrolled